BBC Morning Live doctor issues stark health warning amid Storm Floris
Doctor Punam Krishan, NHS GP and regular on BBC Morning Live, has warned that if you're feeling off, Storm Floris is likely to blame. The second storm of the year is hammering the UK, with people being urged to stay inside their home.
The Met Office has issued two weather alerts - a yellow and an amber warning - both set to expire around midnight. Until then, the health expert advises people to rest, as it's likely no coincidence that you may be experiencing headaches, fatigue or general body aches and pains.
Taking to her Instagram to explain to people what's happening, Dr Punam said: "Storm Floris is rolling through the UK. We are getting absolutely hammered up here in Scotland, but alongside the chaos that this kind of weather brings, I wanted to share how it [weather] can affect your health as well.
"So if your head has been pounding over the last 12 hours or you are feeling a wee bit off today, it might not be a coincidence."
She notes that her patients have told her that they can feel a migraine build just before a storm - and there is actually science behind why this happens.
The NHS GP explains: "When the air pressure suddenly drops, like it does during a storm, it can trigger pressure changes inside your head as well, So for people who are sensitive, that can be enough to spark a migraine.
"And it's not just migraines, people often notice things like aching joints, sinus pressure changes, tiredness, even a bit of brain fog when the weather suddenly changes. I always find it so fascinating how many people feel the storm coming before they've even seen the weather forecast."
With this in mind, the Strictly Come Dancing star reassures people that "if you're not feeling 100 per cent today, give yourself a break, stay hydrated, rest if you can, and if you are prone migraines, it's absolutely fine to take it easy and take your usual treatment early."
Concluding her health advice, she urges the public to heed warnings from official sources like the Met Office, advising that people should only leave their homes if absolutely necessary. She stressed: "Take note of the weather warnings. If you don't need to go out, stay safe inside and let's hope Storm Floris does her thing quickly and she moves on."
Met Office issues two weather warnings amid Storm Floris
The Met Office has issued two urgent weather warnings as Storm Floris batters the UK with heavy rain and winds reaching up to 85mph in some areas. These conditions have led to significant travel disruptions, including delays to trains and even flight cancellations and delays.
Officials are urging people to stay home and avoid all non-essential travel. If you must go out, extreme caution is advised. The yellow wind warning remains in place for much of the UK until midnight.
Meanwhile, a more severe amber wind warning, which was issued yesterday, is affecting Scotland. This warning began at 10am today and will stay in force until 11pm.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Scottish Sun
28 minutes ago
- Scottish Sun
New cancer treatment that slashes risk of death by a quarter gives fresh hope to thousands in ‘major step forward'
Click to share on X/Twitter (Opens in new window) Click to share on Facebook (Opens in new window) WOMEN with advanced womb cancer have been given fresh hope with the approval of a new drug. The treatment, which can slash the risk of death by 26 per cent, was given the green light for widespread NHS use. Sign up for Scottish Sun newsletter Sign up 1 Pembrolizumab, also known as Keytruda, has been licensed to treat advanced or recurring endometrial cancer Credit: Alamy Just 15 per cent of women live for five years if they have been diagnosed with advanced endometrial cancer - a cancer which usually starts in the lining of the womb. The National Institute for Health and Care Excellence (NICE) has now made a treatment, called pembrolizumab, available on the NHS in England for people with advanced or recurring endometrial cancer. The drug can slow down cancer growth and improve survival odds, health officials said. NICE estimates that around 2,100 women will benefit from the treatment each year. It said that its approval of the treatment marks a "major step forward" in treatment for women with this type of cancer. Pembrolizumab, also known as Keytruda and made by Merck Sharp and Dohme, is an immunotherapy drug. This is a type of treatment that mobilises the body's own immune system to fight cancer. The drug is delivered in a drip alongside chemotherapy drugs carboplatin and paclitaxel and can be given to patients for up to two years. According to NICE, clinical trials show the combination of treatments reduced the risk of death by 26 per cent compared to chemotherapy alone. The drug combo can also slow down cancer progression, the regulator added. Cervical cancer warning signs you should NEVER ignore, with Doctor Philippa Kaye Helen Knight, director of medicines evaluation at NICE, said: "For people with advanced endometrial cancer, this innovative combination offers a powerful new treatment option. "It marks a major step forward, and we're pleased to recommend it as part of our commitment to getting the best care to people, fast, while ensuring value for the taxpayer." Around 9,700 women are diagnosed with endometrial cancer - also known as womb or uterine cancer - each year, making it the most common gynaecological cancer in the UK, according to NICE. The disease is most common in older women. Womb cancer symptoms Cancer of the womb is often called uterine or endometrial cancer. Symptoms include: Bleeding after the menopause Bleeding that is unusually heavy or persistent between periods Abnormal vaginal discharge (this might be pink) Anaemia High platelet count High blood sugar levels Stomach pain Swollen tummy Bloating Change in bowel or bladder habits A new cough Being overweight or obese is one of the biggest risks of womb cancer, according to Cancer Research UK. Other risk factors include age (most women diagnosed are aged 75 to 79) as well as being on hormone replacement therapy (HRT) and having diabetes or polycystic ovary syndrome (PCOS). Having too much of the hormone oestrogen is thought to raise your risk of womb cancer, according to the Eve Appeal. Fat cells in the body store oestrogen, even after the menopause and obesity has been linked to womb cancer because of its effect on oestrogen levels. It's not always possible to prevent womb cancer, but some things are thought to reduce your risk, like maintaining a healthy weight. Source: Cancer Research UK Its most common symptom is abnormal bleeding from the vagina, that is heavier than usual and occurs between periods or after menopause. It can also cause pink-tinged vaginal discharge, as well abdominal pain, bloating and a change in bladder or bowel habits. Helen Hyndman, lead nurse at the charity Eve Appeal's information service Ask Eve, said: "Primary advanced or recurrent womb (endometrial) cancer has a huge impact on the quality of life for those diagnosed. "It is great news that this new treatment has been approved. "It will offer hope, a better quality of life and improve outcomes for those affected."
The Sun
34 minutes ago
- The Sun
New cancer treatment that slashes risk of death by a quarter gives fresh hope to thousands in ‘major step forward'
WOMEN with advanced womb cancer have been given fresh hope with the approval of a new drug. The treatment, which can slash the risk of death by 26 per cent, was given the green light for widespread NHS use. 1 Just 15 per cent of women live for five years if they have been diagnosed with advanced endometrial cancer - a cancer which usually starts in the lining of the womb. The National Institute for Health and Care Excellence (NICE) has now made a treatment, called pembrolizumab, available on the NHS in England for people with advanced or recurring endometrial cancer. The drug can slow down cancer growth and improve survival odds, health officials said. NICE estimates that around 2,100 women will benefit from the treatment each year. It said that its approval of the treatment marks a "major step forward" in treatment for women with this type of cancer. Pembrolizumab, also known as Keytruda and made by Merck Sharp and Dohme, is an immunotherapy drug. This is a type of treatment that mobilises the body's own immune system to fight cancer. The drug is delivered in a drip alongside chemotherapy drugs carboplatin and paclitaxel and can be given to patients for up to two years. According to NICE, clinical trials show the combination of treatments reduced the risk of death by 26 per cent compared to chemotherapy alone. The drug combo can also slow down cancer progression, the regulator added. Cervical cancer warning signs you should NEVER ignore, with Doctor Philippa Kaye Helen Knight, director of medicines evaluation at NICE, said: "For people with advanced endometrial cancer, this innovative combination offers a powerful new treatment option. "It marks a major step forward, and we're pleased to recommend it as part of our commitment to getting the best care to people, fast, while ensuring value for the taxpayer." Around 9,700 women are diagnosed with endometrial cancer - also known as womb or uterine cancer - each year, making it the most common gynaecological cancer in the UK, according to NICE. The disease is most common in older women. Womb cancer symptoms Cancer of the womb is often called uterine or endometrial cancer. Symptoms include: Bleeding after the menopause Bleeding that is unusually heavy or persistent between periods Abnormal vaginal discharge (this might be pink) Anaemia High platelet count High blood sugar levels Stomach pain Swollen tummy Bloating Change in bowel or bladder habits A new cough Being overweight or obese is one of the biggest risks of womb cancer, according to Cancer Research UK. Other risk factors include age (most women diagnosed are aged 75 to 79) as well as being on hormone replacement therapy (HRT) and having diabetes or polycystic ovary syndrome (PCOS). Having too much of the hormone oestrogen is thought to raise your risk of womb cancer, according to the Eve Appeal. Fat cells in the body store oestrogen, even after the menopause and obesity has been linked to womb cancer because of its effect on oestrogen levels. It's not always possible to prevent womb cancer, but some things are thought to reduce your risk, like maintaining a healthy weight. Its most common symptom is abnormal bleeding from the vagina, that is heavier than usual and occurs between periods or after menopause. It can also cause pink-tinged vaginal discharge, as well abdominal pain, bloating and a change in bladder or bowel habits. Helen Hyndman, lead nurse at the charity Eve Appeal's information service Ask Eve, said: "Primary advanced or recurrent womb (endometrial) cancer has a huge impact on the quality of life for those diagnosed. "It will offer hope, a better quality of life and improve outcomes for those affected."
Western Telegraph
an hour ago
- Western Telegraph
Treatment for advanced womb cancer ‘major step forward'
Just 15% of women live for five years if they have been diagnosed with advanced (stage four) endometrial cancer – a cancer which usually starts in the lining of the womb. The treatment, pembrolizumab, can slow down cancer growth and improve survival odds, health officials said. The National Institute for Health and Care Excellence (Nice) estimates that around 2,100 women will benefit from the treatment each year. It said that its approval of the treatment for the NHS in England marks a 'major step forward' in treatment for women with this type of cancer. The treatment, also known as Keytruda and made by Merck Sharp and Dohme, is an immunotherapy drug and is delivered in a drip alongside chemotherapy drugs carboplatin and paclitaxel and can be given for up to two years. Nice said that clinical trials show the combination of treatments reduced the risk of death by 26% compared to chemotherapy alone. The treatments can also slow down cancer progression, it added. 'For people with advanced endometrial cancer, this innovative combination offers a powerful new treatment option,' said Helen Knight, director of medicines evaluation at Nice. 'It marks a major step forward, and we're pleased to recommend it as part of our commitment to getting the best care to people, fast, while ensuring value for the taxpayer.' Around 9,700 women are diagnosed with endometrial cancer each year, Nice said, making it the most common gynaecological cancer in the UK. Helen Hyndman, lead nurse at the charity Eve Appeal's information service Ask Eve, said: 'Primary advanced or recurrent womb (endometrial) cancer has a huge impact on the quality of life for those diagnosed. 'It is great news that this new treatment has been approved. 'It will offer hope, a better quality of life and improve outcomes for those affected.' Professor Peter Johnson, NHS England's national clinical director for cancer, said: 'Getting this treatment to many more NHS patients as quickly as possible will help thousands of women live longer, allowing them to spend more time with loved ones and give them a better quality of life. 'Thanks to the NHS's Cancer Drugs Fund, it is now being fast-tracked into routine use, with treatment available to more patients from today.'
